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Abstract 
 
Molecular analysis of cancer, at the genomic level, could lead to individualized patient 
diagnostics and treatments. The developments to follow will signal a significant paradigm shift 
in the clinical management of human cancer. Despite our initial hopes, however, it seems that 
simple analysis of microarray data cannot elucidate clinically significant gene functions and 
mechanisms. Extracting biological information from microarray data requires a complicated path 
involving multidisciplinary teams of biomedical researchers, computer scientists, 
mathematicians, statisticians, and computational linguists. The integration of the diverse outputs 
of each team is the limiting factor in the progress to discover candidate genes and pathways 
associated with the molecular biology of cancer. Specifically, one must deal with sets of 
significant genes identified by each method and extract whatever useful information may be 
found by comparing these different gene lists. Here we present our experience with such 
comparisons, and share methods developed in the analysis of an infant leukemia cohort studied 
on Affymetrix HG-U95A arrays. In particular, spatial gene clustering, hyper-dimensional 
projections, and computational linguistics were used to compare different gene lists. In spatial 
gene clustering, different gene lists are grouped
 
together and visualized on a three-dimensional 
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expression map, where genes with similar expressions are co-located. In another approach, 
projections from gene expression space onto a sphere clarify how groups of genes can jointly 
have more predictive power than groups of individually selected genes. Finally, online literature 
is automatically rearranged to present information about genes common to multiple groups, or to 
contrast the differences between the lists. The combination of these methods has improved our 
understanding of infant leukemia. While the complicated reality of the biology dashed our initial, 
optimistic hopes for simple answers from microarrays, we have made progress by combining 
very different analytic approaches. 
 
Analysis techniques for molecular classification in infant leukemia  
 
Advances in the treatment and prognosis of childhood leukemia are considered remarkable 
successes in modern medicine (Greaves, 2002). However, even using the current risk 
classification systems (combining age, white blood cell count at presentation (WBC), 
morphology, cytogenetics, and other biologic parameters), infants with leukemia who will 
ultimately achieve complete clinical remission cannot be precisely identified (Biondi, 2000). 
Notably, those patients who will be primarily resistant, or more prone to relapse, are simply not 
completely predicted by cytogenetic parameters; they are distributed among all clinically defined 
risk groups. Refined recognition of patients who will respond to the less intensive therapies 
would be very desirable, particularly to increase survival and decrease therapy-related toxicity 
(Felix, 1999; Biondi, 2000). We are addressing the need for such discrimination diagnostics by 
developing gene expression-based classifications using Affymetrix U95Av2 oligonucleotide 
microarrays (with 12,625 probes). Here we discuss the methods used to analyze our infant 
cohort, which is a statistically designed group of 126 infant patients with acute leukemia. Of the 
126 cases, 78 were Acute Lymphoid Leukemia (ALL, 62%), 48 were Acute Myeloid Leukemia 
(AML, 38%). In addition, 53 cases (42%) had translocations involving the MLL gene 
(chromosome segment 11q23), see Figure 1. 
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Figure 1. Design of the leukemia cohort. The statistically designed cohort contained 126 acute leukemia 
samples from infant patients. Of the 126 cases, 78 were Acute Lymphoid Leukemia (ALL, 62%), 48 were 
Acute Myeloid Leukemia (AML, 38%), and 56 (44%) cases had translocations involving the MLL gene 
(chromosome segment 11q23). Cases were studied using Affymetrix U95Av2 oligonucleotide 
microarrays (12,625 probes). 
 
Traditionally, the analysis of microarray data has used both unsupervised methods, which group 
together genes or patients based on quantitative similarities in expression, and supervised 
approaches, which exploit knowledge available in a training set to predict unknown groups of 
genes or patients. We began our analysis with an unsupervised search for two traits: 1) gene 
expression profiles related to leukemia type (AML vs. ALL, as defined by traditional 
morphology standards), and 2) clinical outcome (remission vs. failure) in infant patients. 
Principal Component Analysis (PCA) (see Joliffe, 1986) was used to determine whether an 
apparent partition could be seen between the expression profiles of cases in each one of the 
classes (specifically, ALL versus AML and remission versus failure cases).  
 
As shown in Figure 2, PCA uncovers a clear separation between the lymphoid cases (in blue) 
and the myeloid cases (in red). In fact, the first three principal components capture the infant 
ALL/AML lineage distinction. However, PCA failed to find a clear partition between the 
remission (shown in pink, Figure 3) and the failure cases (shown in green, Figure 3). In general, 
and despite an array of different methods, we found that predicting resistance and treatment 
failure was a much more complex problem than the “type” classification (ALL vs. AML). 
 
 
Figure 2. Principal Components Analysis (PCA) ALL/AML separation. The figure shows the projections 
of the first and second (left panel) and third and fourth (right panel) principal components of the infant 
microarray data (using all genes). Each sphere represents an infant sample in the “gene expression” 
dimension. A separation of the gene expression profiles of lymphoid cases (ALL, shown in blue) versus 
the myeloid cases (AML, shown in red) can be seen in the third and fourth PCA projections. 
 6
 
 
 
 
 
Figure 3. Principal Components Analysis (PCA) remission vs. failure separation. The figure shows two-
dimensional projections of the first and second (left panel) and second and third (right panel) principal 
components of the infant microarray data (all genes included). Each sphere represents an infant sample in 
the “gene expression” dimension, and is color-coded to indicate the specific outcome of the case: 
remission (pink) or failure (green). The first three principal components captured the infant ALL/AML 
lineage distinction (Figure 2), but failed in demonstrating a partition between remission and failure cases. 
 
The next step in our analysis involved using supervised learning methods to predict patient 
outcome. Supervised learning methods are trained to recognize “known classes”, creating 
classification algorithms that may be able to predict new cases.  These algorithms are also 
capable of uncovering interesting and novel therapeutic targets by way of gene selection. A 
supervised method needs a training set (known examples) and a test set (for evaluating the 
effectiveness of the classifier). For these methods, the 126 infant samples were divided into 
representative training (82 cases) and test sets (44 cases), statistically balanced according to the 
clinical labels (leukemia lineage, cytogenetics and outcome).  
 
Several supervised class prediction approaches were used including: Bayesian networks (Helman 
et al. 2002), Recursive Feature Elimination in the context of Support Vector Machines (SVM-
RFE) (Guyon et al. 2002), Neuro-Fuzzy Logic, and Discriminant Analysis. These classification 
algorithms were evaluated using fold-dependent, leave-one-out, cross validation (LOOCV) 
techniques. As shown in Table 1, outcome prediction (remission versus failure) was particularly 
poor for all of the methods employed. 
 
Parallel comparison of discriminating genes 
 
The process of defining the best set of discriminating genes identified by the different methods is 
difficult. Different methods of gene selection typically produce different lists of genes (note that  
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this is not necessarily bad because related genes can be essentially equally predictive). We 
developed two main methods for visualizing many gene lists at once and consequently 
comparing not only the lists but also the methods that produced them.  
 
It is reasonable to imagine that two different gene lists carry nearly the same information if the 
genes in the lists generally cluster near each other. We tested this approach with an unsupervised 
clustering algorithm (Kim et al., 2001) that uses Pearson’s correlation coefficient to estimate the 
similarity between any
 
pair of genes. The 20 strongest positive correlations between each gene 
and its neighbors were used
 
to assign that gene to an x-y coordinate in the two-dimensional plane 
using force-directed placement (Davidson et al., 2001). In this
 
x-y ordination step, genes are 
positioned relative to each other
 
under the influence of attractive and repulsive forces. Each gene
 
is attracted to other genes with a force proportional to their
 
similarity in gene expression, and is 
repelled by a constant force proportional the local density of genes.  A computer
 
program called 
VxInsight was used to visualize the spatial distribution
 
of the genes, resulting in a visualization 
wherein genes with a high
 
correlation are placed near each other.  As a further visual cue, the 
two-dimensional
 
scatter plot is converted into a three-dimensional terrain map
 
in which the z-axis 
denotes the density of genes within a given area. The genes identified by the various supervised 
methods were highlighted, and colored as shown in Figures 4 and 5. Not surprisingly, the gene 
lists that are successful in differentiating between ALL and AML do cluster near each other, as 
seen in Figure 4. However, as the various methods have difficulty with the remission/failure 
prediction, it is reasonable to assume that there is no readily identifiable set of differentiating 
genes for this prediction, and indeed, the various methods have no consensus and the suggested 
genes are scattered widely across the overall gene clusters (See Figure 5). 
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Table 1. Class Predictor Performance  
 
Bayesian Net SVM Fuzzy Inference Discriminant 
Analysis 
Description 
r p-value
1 
r p-value
1 
r p-value
1 
r p-value
1 
ALL vs. AML .912 <.001** .971 <.001** .971 <.001** .853 <.001** 
Remission. vs. Fail .568 .256 .622 .094 .405 .906 .568 .256 
Remission. vs. Fail in ALL .542 .419 .625 .153 .375 .924 .500 .580 
Remission. vs. Fail in AML .461 .709 .769 .046* .461 .709 .461 .709 
 
r   = Success rate. 
p-value1 = Computed estimating the probability of successful prediction. 
*    means that the predictor is significant at level α=0.05 
**  means that the predictor is significant at level α=0.01. 
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Figure 4. Co-localization of ALL vs. AML gene lists in a gene expression map. The genes that 
characterize ALL versus AML samples are shown, with a different color for each of the methods used to 
obtain them (green for Bayesian Networks, yellow for discriminant analysis, blue for Fuzzy logics and 
white for SVM). Very similar lists will be co localized, while lists with bigger variation will be further 
apart. A computer program called VxInsight was used to visualize the spatial distribution of the genes, 
resulting in a display in which genes with a high correlation are placed near to each other on a three-
dimensional terrain map wherein the z-axis denotes the density of genes within an area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Visualization of outcome (remission vs. failure) gene lists in a gene expression map. The genes 
that characterize remission versus failure are shown, with a different color for each one of the methods 
used to obtain them (white for SVM and yellow for Bayesian Networks). Very similar lists will be co-
localized, while lists with bigger variation will be further apart. 
 10
We developed a second method to compare and visualize many gene lists simultaneously. In this 
approach, each gene is considered to be a point in patient-space, where each dimension 
corresponds to a different patient. Since there were 12,625 genes and 126 patients, this spatial 
representation had 12,625 points (samples) in a 126 dimensional space. Of the 12,625 genes we 
only considered about 600 that occurred in the different gene lists, reducing our problem to 600 
genes in 126 dimensions.  Furthermore, because we were mainly interested in how the genes 
compared as discriminators, and not how their actual expression levels compared, we projected 
the genes onto the 126 dimensional unit sphere in patient-space, as shown in Figure 6. 
Geometrically, this corresponds to comparing the “directions” of the genes in the various gene 
lists as opposed to their “magnitudes”. 
 
 
Figure 6. Gene lists projections onto the “126 dimensional unit” sphere in patient space.  This is an 
artificial depiction of the sphere method used to visualize gene lists.  The plane spanned by the first two 
principal components is shown intersecting the unit sphere, and each gene is shown as a point.  The 
method of projecting from the ambient dimensions to the principal component plane is illustrated by first 
following a given point back to the sphere and then to the plane via the vertical lines. 
 
In order to understand this visualization is it useful to imagine a sphere with a plane passing 
through the origin. The sphere corresponds to the unit sphere (the sphere with radius one 
centered at the origin) in the patient space and the plane corresponds to the plane determined by 
the first two principal components.  The first principal component points in the radial direction of 
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the sphere and the second principal component is tangential to the sphere at the sphere’s 
intersection with the first principal component.  It is precisely the first two dimensions that are 
shown in Figure 7.  The vector representing a particular gene will intersect the unit sphere, and 
will be near the arc of the sphere (unit circle) in the plane if it lies in the first two principal 
components.  To the extent that the gene lies out of the plane, the projection of the intersection 
back down onto the plane will lie further inside the arc. The distribution of these projections onto 
that principal component plane suggests how a given method of gene selection identifies 
important genes. 
 
 
 
Figure 7. ALL vs. AML gene lists comparison. The gene lists that characterize ALL versus AML are 
shown, with a different color for each of the methods used to obtain them. In distinguishing infant ALL 
from infant AML we found that most of the genes in the list were co-localized in our representative 
visualization. Compare this plot with the results shown in Figure 8. 
 
One of the main observations that can be made is the division of the gene lists above and below 
the center of the plot (in fact divided by the 2
nd
 principal component).  This division is especially 
noticeable in the Bayesian and discriminant analysis gene lists and is due to the fact that these 
methods are univariate gene selection methods.  The univariate methods rank and subsequently 
select genes as isolated variables, and hence obtain gene lists that are in some sense very 
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redundant.  In contrast, the NeuroFuzzy and SVM methods are multivariate and tend to select 
gene lists that are less redundant and hence not entirely determined by the first two principal 
components. 
 
It is evident from Figure 7 that the gene lists selected for the ALL/AML problem are related. 
Unfortunately, it is equally obvious that the gene lists selected for the remission/failure problem 
are unrelated, as shown using the same analysis in Figure 8. 
 
 
 
Figure 8. Remission vs. Failure gene lists comparison. The gene lists that characterize remission versus 
failure are shown, with a different color for each of the methods used to obtain them. It can be seen in this 
figure that distinguishing remission from failure is a difficult task. 
 
In summary, when distinguishing infant ALL from infant AML we found that most of the list 
were co-localized in our representative visualization (see Figures 4 and 7).  When distinguishing 
remission from failure, on the other hand, we could not arrive at a satisfactory conclusion 
(Figures 5 and 8).  Understanding the relationships between these gene lists was important as we 
evaluated their implications, although the lists alone were not sufficient. We wanted to 
understand the mechanisms of these genes in the context of leukemia. The next section discusses 
how we explored the biology of the genes using one specific gene list. 
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Class discovery in infant leukemia 
 
The unsupervised force-directed clustering method, previously described with respect to gene 
clusters, can also be used to cluster patients. When applied to the infant data using the similarity 
of gene expression profiles between patients, we found the existence of three major groups (as 
shown in Figure 9A), hereafter denoted clusters A, B, and C. We searched for genes with 
different expression patterns across these three groups using analysis of variance (ANOVA). 
This method was applied to order all of the genes with respect to different expressions between 
the groups as shown in Figure 9B. The strengths of these gene lists were studied using statistical 
bootstrapping. The results suggested that the identified groups represented well-separated patient 
subclasses. Analysis of the genes that characterized each one of these clusters revealed patterns 
that implied different characteristics with potential clinical relevance. In particular, the three 
distinct expression profiles are unrelated to type labels or cytogenetics, but are instead 
characterized by genes predominantly expressed and probably related to three independent 
disease initiation mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9A. Cluster-by-patients representation. Results of the force directed algorithm applied to the infant 
dataset. The VxInsight program constructs a mountain terrain over the clusters such that the height of each 
mountain represents the number of elements in the cluster under the mountain, A (n=20), B (n=52) and C 
(n=54). The force-directed clustering algorithm coupled with the VxInsight visualization tool suggested 
the existence of three clusters of infant patients separated by their gene expression patterns, and not 
correlated to the traditional clinical labels (morphology: ALL vs. AML, or cytogenetics: MLL 
rearrangement vs. not 
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Figure 9B. Gene expression “heat map” of the 126 infant samples (left hand side). Panel B shows the 
expression levels of the top 89 genes that distinguish the three subgroups of infant leukemia (right hand 
side) cluster A, B and C; as shown, also, in Figure 9A. Each column represents an infant leukemia sample 
and each row represents the relative expression for a particular gene across the samples. Gene expression 
above the mean, below the mean, and around the mean is shown in shades of red, green and black, 
respectively. 
 
Remarkably, the performance of the supervised, class predictor algorithms improved once the 
classifiers were conditioned within the A, B, and C clusters (see Table 2). We were particularly 
interested in the stability, or sensitivity to change in the data, of the rank ordering for these genes. 
We have previously studied gene list stability by adding increasing amounts of white noise to the 
gene similarities (Davidson et al., 2001). However, we now believe that statistical bootstrapping, 
using the actual data, is a better approach (Efron, 1979). Figure 10 outlines how the original data 
was processed to generate an ordered gene list, and then how 100 random resamplings (with 
replacement) from that original data were created. These additional data sets yield another 100 
gene lists so that each gene in the original list can be annotated to show the range of positions 
assigned to it across the 100 lists from the bootstrap study. Note that the top ranking genes, as 
identified by the original measurements, are generally very near the top of the ordered list of 12,625 
probes. The number one gene has an average rank order of 5.3, and none of the average rank 
orders are below 47, thus increasing our confidence in the stability of the reported list. On the other 
hand, Table 3 shows the list associated with the more difficult problem of separating remission and 
failure. In this case, while the genes are relatively high compared to the total of 12,625, the average 
ranking is much less stable than observed for the AML/ALL distinction. The bootstrap method 
described above addresses list stability, but can be extended to address the null hypothesis, namely, 
there is no significant difference in gene expression between the two classes being contrasted. By 
testing this hypothesis we can compute a p-value for the gene’s significance.
  15
 
 
 
 
Table 2. Overall Success Rates of Class Predictors After Including the A, B, and C Cluster Distinctions  
 
Bayesian Net SVM Fuzzy Inference Discriminant Analysis Task # Description 
r C.I. p-value R C.I. p-value r C.I. p-value r C.I. p-value 
2 Remission. vs. Fail 
.568 [.39, .73] .256 .622 [.45, .78] .094 .405 [.25, .58] .906 .568 [.39, .73] .256 
7 Remission. vs. Fail in VX-GA 
.714 [.29, .96] .226 .714 [.29, .96] .226 .857 [.42, .00] .062 .714 [.29, .96] .226 
8 Remission. vs. Fail in VX-GB 
.688 [.41, .89] .105 .563 [.30, .80] .401 .563 [.30, .80] .401 .438 [.20, .70] .772 
9 Remission. vs. Fail in VX-GC 
.714 [.42, .92] .090 .714 [.42, .92] .089 .500 [.23, .77] .604 .500 [.23, .77] .604 
OnVx R/F Conditioned on VX-Groups 
.703 [.53, .84] .010** .649 [.47, .80] .049* .595 [.42, .75] .162 .514 [.34, .68] .500 
 
 
r = Estimate of the success rate of the class predictor. 
C.I. = 95% confidence interval of the success rate of the class predictor. 
p-value = p-value of hypothesis test [2] (see text).  
*    means that r > 0.5 at significance level α = 0.05. 
**  means that r > 0.5 at significance level α = 0.01. 
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Figure 10. Gene list stability exploration. A schematic showing the bootstrap 
process, where the original data was resampled to create 100 new datasets each of 
which were processed in exactly the same manner as the original data, to produce 
the associated 100 new gene lists. The stability of the original data is assessed from 
the bootstrap distribution; see the text for a more detailed description. 
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Table 3. Top 24 genes that characterize ALL vs. AML 
samples, derived from ANOVA. 
Order ANOVA_F ORF Contrast Bootstrap avg. order Description 
1 160.82 40103_at 852.39  
[1<=[1<=5.3 {<=16} <=18] 
p<=0.001 
villin 2 
2 134.75 39689_at -822.75  
[1<=[1<=10.4 {<=26} <=32] 
p<=0.002 
cystatin C amyloid angiopathy and cerebral 
hemorrhage 
3 134.62 1230_g_at -817.22  
[1<=[1<=12.9 {<=46} <=49] 
p<=0.004 
cisplatin resistance associated 
4 130.95 39062_at -930.76  
[1<=[1<=12.4 {<=41} <=42] 
p<=0.009 
protective protein for beta-galactosidase 
(galactosialidosis) 
5 128.94 36766_at -1389.66  
[1<=[1<=14.4 {<=42} <=46] 
p<=0.004 
ribonuclease RNase A family 2 liver 
eosinophil-derived neurotoxin 
6 124.26 38269_at 794.69  
[1<=[1<=14.8 {<=47} <=60] 
p<=0.005 
protein kinase D2 
7 123.69 41523_at -689.50  
[1<=[1<=14.2 {<=40} <=44] 
p<=0.007 
RAB32 member RAS oncogene family 
8 123.18 36938_at -1003.98  
[1<=[1<=14.0 {<=36} <=40] 
p<=0.003 
N-acylsphingosine amidohydrolase acid 
ceramidase 
9 119.83 40432_at -918.53  
[1<=[1<=17.1 {<=42} <=47] 
p<=0.002 
glucosamine (N-acetyl)-6-sulfatase 
(Sanfilippo disease IIID) 
10 111.60 36879_at -968.73  
[1<=[1<=18.6 {<=70} <=73] 
p<=0.005 
endothelial cell growth factor 1 platelet-
derived 
11 109.22 36889_at -756.72  
[1<=[1<=20.0 {<=58} <=68] 
p<=0.002 
Fc fragment of IgE high affinity I receptor 
for gamma polypeptide precursor 
12 106.12 1096_g_at 1000.03  
[1<=[2<=20.8 {<=47} <=54] 
p<=0.007 
CD19 antigen 
13 101.60 38363_at -1152.58  
[1<=[3<=26.1 {<=69} <=75] 
p<=0.008 
TYRO protein tyrosine kinase binding 
protein 
14 101.57 38604_at 1032.19  
[1<=[7<=23.6 {<=43} <=48] 
p<=0.002 
neuropeptide Y 
15 100.80 37398_at -824.41  
[1<=[4<=27.0 {<=67} <=77] 
p<=0.005 
platelet/endothelial cell adhesion molecule 
CD31 antigen 
16 100.22 41221_at -744.57  
[1<=[2<=24.1 {<=56} <=66] 
p<=0.004 
phosphoglycerate mutase 1 brain 
17 99.00 40310_at -625.93  
[1<=[2<=35.4 {<=78} <=123] 
p<=0.005 
toll-like receptor2 
18 94.81 35926_s_at -1584.41  
[1<=[3<=30.7 {<=68} <=79] 
p<=0.004 
leukocyte immunoglobulin-like receptor 
subfamily B with TM and ITIM domains 
19 94.51 39581_at -736.47  
[1<=[2<=32.0 {<=94} <=96] 
p<=0.009 
cystatin A stefin A 
20 93.87 39994_at -929.11  
[1<=[2<=35.0 {<=92} <=99] 
p<=0.010 
chemokine C-C motif receptor 1 
21 89.53 35012_at -888.77  
[1<=[3<=34.9 {<=76} <=86] 
p<=0.007 
myeloid cell nuclear differentiation antigen 
22 87.53 40282_s_at -904.35  
[1<=[3<=36.0 {<=85} <=111] 
p<=0.008 
adipsin/complement factor D precursor 
23 85.87 39593_at -907.59  
[1<=[4<=47.4 {<=142} <=167] 
p<=0.009 
fibrinogen-like 2 
24 85.71 33856_at -604.82  
[1<=[3<=35.2 {<=86} <=98] 
p<=0.013 
CAAX box 1 
 
Table 3. The 24 genes, out of 12,625, with the greatest F-scores by ANOVA to differentiate 
between ALL and AML samples. Note that these F-scores are only used for ranking, while 
stability is investigated by bootstrapping (see Figure 10). The average order across the 
bootstraps is shown for both an upper 95% confidence band, and for the 95% confidence band 
surrounding the average ranking, which is the bold number. The reported p-value is derived 
from another bootstrap as described in the text. 
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The bootstraps described above resample from the two categories being 
contrasted.  For example, the bootstrap AML cases will be drawn from AML 
patients, and ALL cases are drawn from the ALL patients. However, under the 
null hypothesis that there is no difference in gene expression between these two 
cases (AML or ALL) the bootstrap should not distinguish between the cases when 
resampling. Hence, to test the null hypothesis, the samples are drawn randomly 
from either type to investigate how rare the actual observation would be in the 
absence of a real distinction between AML and ALL gene expressions. To 
compute the significance (p-value) for a gene, we generate 10,000 such 
bootstraps, and observe the fraction of times the gene ranked at or above the list 
order found with the real data. 
These statistics have been very valuable by allowing us to avoid investing large 
amounts of effort into genes that are unlikely to be significant. However, a great 
proportion of the investigative effort still involves reading existing papers and 
other text about each one of the genes in the lists. We recognized that this text 
processing had become a bottleneck in our research. As a result, we investigated 
how Natural Language Processing (NLP) could be employed to help us, as 
described in the following section. 
 
Gene List Exploration Environment 
The next step, in the traditional exploratory analysis of microarray data, is the 
very labor and knowledge intensive work of learning everything that is known 
about these genes, especially with respect to disease and biological pathways. We 
collaborated with computational linguists to build a knowledge-mining tool, 
which we regularly use in our analysis. This first implementation of our Gene List 
Exploration Environment (GLEE program) consists of a simple interface that 
speeds up our search through text about genes identified by any of our 
approaches. A demonstration version of GLEE, together with user documentation, 
is available from Computing Research Laboratory web site:  
http://aiaia.nmsu.edu/. 
The input to the system is a list of gene identifiers from Affymetrix translated by 
the program to the equivalent OMIM gene identifier (See Figure 11, and further 
details at the OMIM web site:  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM). 
As shown in the Figure 12, the relevant OMIM text is retrieved and re-ordered to 
match the criteria that we use for evaluating genes. This automated retrieval and 
reordering also employs text summarization. We are presently in the process of 
extending GLEE to use a subset of the NCI Enterprise Vocabulary Services, EV, 
which is a first step toward a more knowledge-based tool that will be 
implemented with semantic networks. Because so much of our knowledge about 
the functions, localizations, and clinical impacts of genes is encoded in published 
literature, and because the effort to incorporate that knowledge is so labor and 
knowledge intensive we believe the application of NLP to our specific needs is a 
critical, and a still largely missing tool for genomic and proteomic investigations. 
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Figure 11. The Gene Literature Exploration Environment (GLEE) interface is configured 
as a web server, which handles document and query management, and a web browser that 
provides the user interface. 
 
 
 
Figure 12. Output of the GLEE program. Summarized, and reordered annotations of a set 
of genes. Note that this is just the first page of annotations; further annotations are 
available by scrolling down in the browser. 
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Conclusions 
 
Exciting preliminary gene expression profiling studies are providing new insights 
into the molecular mechanism of tumorigenesis in acute leukemia. These studies 
hold promise to impact diagnosis, prognosis, and therapeutic interventions. 
However, the speed at which groups of genes generated by microarray analysis 
can be put together in pathways is one of the limiting steps in the translation of 
these discoveries to clinical applications. 
 
The methods presented here can potentially be useful in uncovering groups of 
genes that serve to fingerprint subtypes of acute leukemia and that could aid in 
refining diagnosis and improving assessment of prognosis. Additionally, gene list 
comparison and exploration methods will increase the speed at which researchers 
can visualize and extract the more complex relationships encoded in gene 
expression data. 
 
The ultimate goal of our multidisciplinary approaches will be to accelerate the 
rate at which the discoveries, derived from high-throughput gene expression 
analysis, can be materialized into better cancer treatments. 
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